These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19385968)

  • 21. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
    DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
    Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
    Resetkova E; Reis-Filho JS; Jain RK; Mehta R; Thorat MA; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2010 Aug; 123(1):97-108. PubMed ID: 19911270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
    Proctor E; Kidwell KM; Jiagge E; Bensenhaver J; Awuah B; Gyan K; Toy K; Oppong JK; Kyei I; Aitpillah F; Osei-Bonsu E; Adjei E; Ohene-Yeboah M; Brewer RN; Fondjo LA; Owusu-Afriyie O; Wicha M; Merajver S; Kleer C; Newman L
    Ann Surg Oncol; 2015 Nov; 22(12):3831-5. PubMed ID: 25743329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
    Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
    Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.
    Georgescu R; Boros M; Moncea D; Bauer O; Coros MF; Oprea A; Moldovan C; Podoleanu C; Stolnicu S
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):533-538. PubMed ID: 28099174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
    Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
    Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.
    Bane A; Viloria-Petit A; Pinnaduwage D; Mulligan AM; O'Malley FP; Andrulis IL
    Breast Cancer Res Treat; 2013 Jul; 140(1):195-205. PubMed ID: 23813303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
    Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
    Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer.
    Kang EJ; Jung H; Woo OH; Park KH; Woo SU; Yang DS; Kim AR; Lee JB; Kim YH; Kim JS; Seo JH
    Neoplasma; 2014; 61(3):352-62. PubMed ID: 24824938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization.
    Gradilone A; Naso G; Raimondi C; Cortesi E; Gandini O; Vincenzi B; Saltarelli R; Chiapparino E; Spremberg F; Cristofanilli M; Frati L; Aglianò AM; Gazzaniga P
    Ann Oncol; 2011 Jan; 22(1):86-92. PubMed ID: 20603432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel prognostic markers for patients with triple-negative breast cancer.
    Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
    Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
    Guarneri V; Dieci MV; Bisagni G; Frassoldati A; Bianchi GV; De Salvo GL; Orvieto E; Urso L; Pascual T; Paré L; Galván P; Ambroggi M; Giorgi CA; Moretti G; Griguolo G; Vicini R; Prat A; Conte PF
    Ann Oncol; 2019 Jun; 30(6):921-926. PubMed ID: 30778520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome.
    Tan EY; Thike AA; ; Tan PH
    Br J Cancer; 2013 Jul; 109(1):109-13. PubMed ID: 23787917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.
    Shokouh TZ; Ezatollah A; Barand P
    Medicine (Baltimore); 2015 Aug; 94(32):e1359. PubMed ID: 26266392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers.
    Murase K; Yanai A; Saito M; Imamura M; Miyagawa Y; Takatsuka Y; Inoue N; Ito T; Hirota S; Sasa M; Katagiri T; Fujimoto Y; Hatada T; Ichii S; Nishizaki T; Tomita N; Miyoshi Y
    Breast Cancer; 2014 Jan; 21(1):52-7. PubMed ID: 22359195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis.
    Dong Y; Bi LR; Xu N; Yang HM; Zhang HT; Ding Y; Shi AP; Fan ZM
    Pathol Res Pract; 2013 Sep; 209(9):555-61. PubMed ID: 23916993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.